(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of -16.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Arbutus Biopharma's revenue in 2024 is $12,986,000.On average, 3 Wall Street analysts forecast ABUS's revenue for 2024 to be $1,402,170,349, with the lowest ABUS revenue forecast at $1,151,176,195, and the highest ABUS revenue forecast at $1,849,430,608. On average, 3 Wall Street analysts forecast ABUS's revenue for 2025 to be $1,239,118,507, with the lowest ABUS revenue forecast at $1,094,560,972, and the highest ABUS revenue forecast at $1,471,995,790.
In 2026, ABUS is forecast to generate $1,622,969,717 in revenue, with the lowest revenue forecast at $1,622,969,717 and the highest revenue forecast at $1,622,969,717.